Clinical trials: Palmoplantar Psoriasis
Palmoplantar Psoriasis, Plaque Psoriasis
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
The purpose of this research study is to examine the effect of Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) on plaque type psoriasis of the hands and/or feet.
- Trial name
- NCT04720105
- Testing
- Duobrii®
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Palmoplantar Pustulosis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
- Trial name
- BeSeen (NCT07219420)
- Testing
- Bimekizumab
- Where
- 91 sites in United States, Canada and 11 more
- Volunteers
- 320 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
The purpose of this study is to evaluate the efficacy of guselkumab for the treatment of palmoplantar psoriasis.
- Trial name
- G-PLUS (NCT03998683)
- Testing
- Guselkumab 100 mg
- Where
- 26 sites in France, Germany and 3 more
- Volunteers
- 117 people
- Sponsor
- Janssen-Cilag Ltd.
Palmoplantar Psoriasis, Genital Psoriasis
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.
- Trial name
- NCT06042920
- Testing
- Deucravacitinib
- Where
- 31 sites in United States, Argentina and 1 more
- Volunteers
- 130 people
- Sponsor
- Bristol-Myers Squibb
Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau
Anakinra for Inflammatory Pustular Skin Diseases
Background: Inflammatory pustular skin diseases are a type of autoinflammatory disease in which the immune system attacks the bodys tissues.
- Conditions
- Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau, Pustular Psoriasis, Palmoplantar Pustulosis
- Trial name
- NCT01794117
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Palmoplantar Pustulosis (PPP)
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
The primary objective is to provide dose-ranging data for 4 dose regimens of BI 655130 compared to placebo on the primary endpoint of percentage change from baseline in PPP ASI at Week 16.
- Trial name
- NCT04015518
- Testing
- Spesolimab
- Where
- 88 sites in United States, Australia and 13 more
- Volunteers
- 152 people
- Sponsor
- Boehringer Ingelheim
Palmoplantar Pustular Psoriasis
Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab
A one year study assessing the efficacy and safety of secukinumab compared with placebo in adult patients with moderate to severe palmoplantar pustular psoriasis - amended with an optional extension treatment period of up to a…
- Trial name
- NCT02008890
- Testing
- Secukinumab 300mg, Secukinumab 150mg
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 237 people
- Sponsor
- Novartis Pharmaceuticals
Palmoplantaris Pustulosis
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis
This study will evaluate whether apremilast is better than placebo (inactive substance in the same form as the drug) for the treatment in Japanese subjects with PPP.
- Trial name
- NCT04057937
- Testing
- Apremilast
- Where
- 22 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Amgen
Palmoplantar Pustulosis (PPP)
Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis
Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease primarily affecting the palms and soles. Currently, no treatment is specifically approved for PPP globally.
- Trial name
- NCT07530367
- Testing
- Tofacitinib, Imatinib
- Where
- China
- Volunteers
- 135 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pustular Psoriasis (PP)
International Rare And Severe Psoriasis Expert Network
This registry is a prospective observational study in order to describe primarily the natural course of PP subtypes and to gain detailed information about their phenotype.
- Trial name
- IRASPEN (NCT04359394)
- Testing
- biological sampling, Phenotypic description, Photography
- Where
- 8 sites in Germany, Italy and 4 more
- Volunteers
- 180 people
- Sponsor
- University Hospital, Basel, Switzerland
Psoriasis, Skin or Nails
Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles
Psoriasis is a common skin disease that can affect 1-3% of the population. For more severe psoriasis, oral medication such as acitretin is sometimes given.
- Trial name
- NCT02181790
- Testing
- Excimer laser, Acitretin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Palmoplantar Pustulosis
Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis
The goal of this clinical trial is to investigate the efficacy and safety of Deucravacitinib in patients with moderate-to-severe palmoplantar pustulosis.
- Trial name
- NCT07000630
- Testing
- Deucravacitinib
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Peking University First Hospital
Psoriasis
Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients
The primary objective of this trial is to investigate the safety and efficacy of BI 655130 in patients with PPP following multiple intravenous administrations compared to placebo.
- Trial name
- NCT03135548
- Testing
- Spesolimab (low dose), Spesolimab (high dose)
- Where
- 18 sites in Canada, Denmark and 4 more
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Palmoplantar Pustulosis (PPP)
Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis
Palmoplantar pustulosis (PPP) is a chronic and recurrent skin disease, mainly characterized by erythema, pustules and scales on the palms and soles, often accompanied by itching and pain, which seriously affects the quality of…
- Trial name
- NCT07503652
- Testing
- Xeligekimab Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- First Hospital of China Medical University
Moderate to Severe Palmoplantar Psoriasis
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
Purpose of the study was to demonstrate the efficacy of secukinumab versus placebo on palmoplantar psoriasis and to assess the long term efficacy, safety and tolerability of secukinumab.
- Trial name
- GESTURE (NCT01806597)
- Testing
- secukinumab 150 mg, secukinumab 300 mg
- Where
- 54 sites in United States, Australia and 13 more
- Volunteers
- 205 people
- Sponsor
- Novartis Pharmaceuticals
Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP)
Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions.
- Conditions
- Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP), Eczema Atopic Dermatitis, Acute Generalized Exanthematous Pustulosis
- Trial name
- LegitHealth BI (NCT07428915)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- AI Labs Group S.L
Psoriasis Palm & Soles
Treatment of Palmoplantar Psoriasis With Low Doses Interferential Current
Interferential current has shown promising results for treating psoriasis with a good tolerance. Prospective randomized studies versus placebo are required to confirm the interest of such an approach.
- Trial name
- NCT01765985
- Testing
- PSORIAMED
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Pr PASSERON
Acne, Atopic Dermatitis
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.
- Conditions
- Acne, Atopic Dermatitis, Chronic Hand Eczema, Hidradenitis Suppurativa
- Trial name
- NCT05994976
- Testing
- Blood samples collection, Oral samples collection, Hair samples collection
- Where
- Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Innovaderm Research Inc.
Palmoplantar Pustulosis
An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis
The purpose of this study is to evaluate the efficacy and safety of guselkumab for the treatment of participants with palmoplantar pustulosis.
- Trial name
- NCT02641730
- Testing
- Guselkumab
- Where
- 32 sites in Japan
- Volunteers
- 159 people
- Sponsor
- Janssen Pharmaceutical K.K.
Hidradenitis Suppurativa, Palmoplantar Pustulosis
Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis
Study CSL324_1002 will investigate the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis.
- Trial name
- NCT03972280
- Testing
- Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
- Where
- 11 sites in Australia, Denmark and 1 more
- Volunteers
- 39 people
- Sponsor
- CSL Behring